Subgroup analysis revealed that ARBs, such as losartan, provided greater survival benefits than ACEi (CSM HR: 0.42 vs. 0.85), which is consistent with findings in Section 3.2 that highlight the more specific inhibition of pro-tumor AT1R by ARBs [44]. The gene discussed is AGTR1; the disease is neoplasm.